Oraxol clinical trials
How each study uses Oraxol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Athenex, Inc. (9) · Health Hope Pharma (1) · Kinex Pharmaceuticals Inc. (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Studies
Open first, then newest update. How each study uses Oraxol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer PatientsCompletedPhase 1Health Hope PharmaNCT03165955Written as OraxolHow we know
- The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as OraxolTerminatedPhase 1Athenex, Inc.NCT03892018Written as OraxolHow we know
- A Study of Oraxol in Subjects With Cutaneous AngiosarcomaCompletedPhase 2Athenex, Inc.NCT03544567Written as OraxolHow we know
- Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid TumorsTerminatedPhase 1Athenex, Inc.NCT03588039Written as OraxolHow we know
- Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast CancerCompletedPhase 3Athenex, Inc.NCT02594371Written as OraxolHow we know
- An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007TerminatedPhase 1Athenex, Inc.NCT04168957Written as OraxolHow we know
- Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal CancersStatus unknownPhase 1Athenex, Inc.NCT02970539Written as OraxolHow we know
- A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. MalignanciesCompletedPhase 1Athenex, Inc.NCT02730481Written as OraxolHow we know
- A PK Study of Oraxol in Breast Cancer PatientsCompletedPhase 1Athenex, Inc.NCT04993040Written as OraxolHow we know
- A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer PatientsCompletedPhase 2Athenex, Inc.NCT04180384Written as OraxolHow we know
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced MalignanciesCompletedPhase 1Kinex Pharmaceuticals Inc.NCT01967043Written as OraxolHow we know